Home›Research›Compare›Cagrilintide vs CJC-1295 DAC
Peptide ComparisonCagrilintide vs CJC-1295 DAC
Cagrilintide
AM833
Half-life: ~7 days
20 providers listed
CJC-1295 DAC
CJC-1295 with DAC
Half-life: 6–8 days
No providers listed yet
Cagrilintide and CJC-1295 DAC target different goals — Cagrilintide for Metabolic, CJC-1295 DAC for GH and IGF-1 elevation studied in a single-dose human PK trial. They're compared here for reference, not as direct substitutes.
Cagrilintide
Evidence
Half-life
~7 days
CJC-1295 DAC
Evidence
Half-life
6–8 days
Cagrilintide and CJC-1295 DAC target different goals — Cagrilintide for Metabolic, CJC-1295 DAC for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
Cagrilintide
CJC-1295 DAC
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+6 more
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About CJC-1295 DAC
CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
CJC-1295 DAC
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceCagrilintide
CJC-1295 DAC
Where to source these peptides
Cagrilintide
20 listed
Browse directory →
Providers offeringCJC-1295 DAC
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs CJC-1295 DAC — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/cjc-1295-dac